In 2023, M&A transactions in the global pharmaceutical and health field will be active. From the perspective of mergers and acquisitions, leading companies focus on increasing their layout in oncology, neuroscience, rare diseases and other fields. In terms of M&A scale, the world's top 10 M&A events totaled $115.2 billion, with a single transaction amount of more than $3.5 billion, of which Pfizer's acquisition of Seagen ranked first with $43 billion.
辉瑞430亿美元收购Seagen
In December 2023, Pfizer announced the completion of the acquisition of Seagen at $229 per share, with a total value of approximately $43 billion. The acquisition will provide Pfizer with a pipeline of four approved products and antibody-drug drug conjugate candidates to strengthen its cancer treatment pipeline. Pfizer said it expects the products from the acquisition of Seagen to generate an additional $10 billion in annual revenue by 2030.
As a pioneer in antibody-drug drug conjugates, Seagen is committed to developing innovative anti-cancer therapies. According to the NextPat patent database search, Seagen has more than 100 patent families, and the types of patents it has applied for comprehensively cover the antibody-drug conjugate track, including compounds, sequences, medical uses and compositions.
Seagen pipeline situation. Seagen's official website
百时美施贵宝140亿美元收购Karuna
In December 2023, Bristol-Myers Squibb announced the acquisition of Karuna Therapeutics for a total of approximately $14 billion to expand Bristol-Myers Squibb's portfolio in neuroscience.
With this acquisition, Bristol-Myers Squibb will have access to Karuna's potential "first-in-class" therapeutic, KarXT, which has been approved by the U.S. Food and Drug Administration for the treatment of schizophrenia in adults and which, if approved, would be the first new mechanism for the treatment of schizophrenia in decades.
Karuna pipeline situation. Karuna's official website Figure
Merck acquires Prometheus for $10.8 billion
In June 2023, Merck announced the completion of the acquisition of Prometheus Biosciences for a total of $10.8 billion, making Prometheus a wholly owned subsidiary of Merck. Merck strengthens its pipeline in the immunology space with the acquisition of new drug candidates for ulcerative colitis, Crohn's disease and other autoimmune diseases.
Prometheus is a clinical-stage biotechnology company that uses precision medicine approaches to discover, develop, and commercialize novel therapeutic and ancillary diagnostic products for the treatment of immune-mediated diseases. At present, the company has disclosed 5 drugs under development.
Prometheus Pipeline Situation. Prometheus official website map
AbbVie acquires ImmunoGen for $10.1 billion
In November 2023, AbbVie announced the acquisition of ImmunoGen for $10.1 billion, which is expected to close in 2024. AbbVie will acquire its "first-in-class" antibody-drug conjugate, Elahere, which aims to strengthen its oncology pipeline and accelerate its entry into solid tumors.
ImmunoGen is one of the first companies in the world to develop antibody-drug conjugates, and its pipeline includes potential projects for the treatment of a variety of different solid tumors and hematologic malignancies. AbbVie expects to accelerate its growth in the treatment of ovarian cancer through ImmunoGen's late-stage development program for Elahere, which is expected to expand the therapy to the early stage of ovarian cancer treatment as well as other patient populations.
ImmunoGen pipeline situation. ImmunoGen official website map
艾伯维87亿美元收购Cerevel
In December 2023, AbbVie announced the acquisition of Cerevel Therapeutics and its neuroscience pipeline for approximately $8.7 billion. The acquisition of Cerevel's pipeline of clinical-stage and preclinical drug candidates developed to treat conditions such as schizophrenia, Parkinson's disease and mood disorders strengthens AbbVie's presence in neuroscience.
Cerevel pipeline situation. Diagram of Cerevel's official website
渤健73亿美元收购Reata
In July 2023, Biogen announced that it had entered into an agreement with Reata to acquire Reata for $172.5 per share in cash, in a total transaction of approximately $7.3 billion.
Reata is a global biopharmaceutical company focused on developing therapeutics that modulate cellular metabolism and inflammation for severe neurological diseases, and its lead product, omaveloxolone (Skyclarys), was approved by the U.S. Food and Drug Administration in February 2023 and is the first rare disease drug for the treatment of Friedreich's ataxia in adolescents and adults 16 years of age and older.
Reata pipeline situation. Reata's official website Figure
罗氏71亿美元收购Telavant
In October 2023, Roche announced the acquisition of Telavant Holdings for $7.1 billion to acquire the rights to develop, manufacture and commercialize its core product under development, TL1A antibody RVT-3101, in the United States and Japan.
RVT-3101 is a potential "first-in-class" anti-TL1A monoclonal antibody for the treatment of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease, which is currently in Phase III clinical trials.
Astellas acquires Iveric for $5.9 billion
In April 2023, Astellas entered into an agreement with Iveric Bio to acquire the latter for $5.9 billion to expand its footprint in the field of ophthalmic therapies.
Iveric Bio is a biopharmaceutical company focused on the development of ophthalmic therapeutics, including aptamers and AAV gene therapies, and its complement C5 inhibitor, Avacincaptad pegol, has been approved by the U.S. Food and Drug Administration for the treatment of geographic atrophy secondary to age-related macular degeneration.
Iveric pipeline situation. Picture of Iveric's official website
时 48 元 Mirati
In October 2023, Bristol-Myers Squibb and Mirati Therapeutics announced that they had entered into a definitive merger agreement whereby Bristol-Myers Squibb agreed to acquire Mirati for $58 per share in cash, with a total share capital value of $4.8 billion.
Mirati is a biopharmaceutical company focused on developing innovative oncology therapies with a pipeline of novel therapies for cancer genetics and immune drivers. With this acquisition, Bristol-Myers Squibb will gain access to Mirati's KRAS G12C inhibitor, Krasati (adagrasib), as well as several oncology clinical pipelines with potential for future development as monotherapy and combination therapies.
Mirati pipeline situation. Picture of the official website of Mirati company
诺华35亿美元收购Chinook
In August 2023, Novartis announced that it had completed the acquisition of Chinook Therapeutics in a transaction valued at up to $3.5 billion. Novartis said the acquisition will expand the company's kidney portfolio and complement its existing pipeline.
Chinook Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of precision medicines in the field of kidney disease. The Company has two high-value, advanced drugs for the treatment of rare, severe chronic kidney disease for the treatment of immunoglobulin A nephropathy (IgA nephropathy) and aims to provide targeted treatment options to more patients.
Chinook pipeline situation. Chinook official website Figure